TOPACIO: what clinicians are saying
niraparib plus pembrolizumab in advanced triple-negative breast cancer or recurrent ovarian cancer · NCT02657889 ↗ · Phase 1/Phase 2 · Tesaro, Inc.
A surgical oncologist reads TOPACIO as suggesting the drugs work better together, citing BRCA-wild-type ovarian responses. Another speaker finds the drugs’ contributions difficult to separate in TNBC; a speaker described in the sources as involved in the trial sees TNBC responses as similar to PARP monotherapy. The ovarian and TNBC observations are not directly matched. Genomic and immune markers still need validation before they can guide treatment selection.
Created with AI · how we check it
- edition 1
- commentary checked Nov 15, 2026
- 183 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. Niraparib plus pembrolizumab: where speakers split on what the combination adds
1 of the report's 6 cited clinicians · 11 statements from 3 speakers in 5 sources, 2 of them podcasts or videos · 10 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, The comparison, Population and setting, Secondary endpoints.
02. Niraparib plus pembrolizumab: a clinician cites activity but notes no NCCN listing
1 of the report's 6 cited clinicians · 11 statements from 2 speakers in 3 sources, all podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, Population and setting, Secondary endpoints.
03. Activity beyond BRCA: most speakers see it, but some seek selection markers
4 of the report's 6 cited clinicians · 22 statements from 7 speakers in 10 sources, 3 of them podcasts or videos · 19 passages
Limitations recorded: 3.
Draws on: Population and setting, Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, The comparison, Safety and tolerability.
04. TOPACIO response data: what speakers highlight, but one notes ORR fell
2 of the report's 6 cited clinicians · 24 statements from 9 speakers in 19 sources · 21 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, Secondary endpoints, Population and setting, The comparison.
05. Tolerability in breast cancer: where speakers split on which patients it covers
1 of the report's 6 cited clinicians · 6 statements from 2 speakers in 4 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Population and setting.
06. PARP–immunotherapy rationale: speakers support it, but claim no clinical synergy
1 of the report's 6 cited clinicians · 23 statements from 2 speakers in 2 sources, all podcasts or videos · 11 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, The comparison.
Beyond the trial population
07. Platinum resistance: how speakers weigh therapy, supportive care and when to stop
1 of the report's 6 cited clinicians · 24 statements from 2 speakers in 2 sources, all podcasts or videos · 10 passages
Limitations recorded: 5.
08. Platinum resistance: why a clinician favors immunochemotherapy over PD-1 drugs alone
1 of the report's 6 cited clinicians · 11 statements from 1 speaker in 2 sources, all podcasts or videos · 8 passages
Limitations recorded: 4.
09. MEDIOLA triplet: a speaker favors it, but leaves its advantage open
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 1 source, a podcast or video · 1 passage
Limitations recorded: 3.
10. PARP combinations: a speaker looks to biopsies, macrophages and priming
No named clinician · accounts and unnamed speakers · 30 statements from 1 speaker in 1 source, a podcast or video · 15 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
1 of the report's 6 cited clinicians
Niraparib plus pembrolizumab: where speakers split on what the combination adds
11 statements from 3 speakers in 5 sources, 2 of them podcasts or videos
3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other
- 11
- statements
- 10
- passages
- 5
- sources
- 3
- speakers
What the statements areViews 5Questions and uncertainty 1Clinical experience 0Comparisons 3Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 15Giving context 1Recorded with the findingLimitations: 3
1 post or article · 2 podcasts and video · 2 publications
Draws on: Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, The comparison, Population and setting, Secondary endpoints.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
4 of the 10 findings and 62 of the 183 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Physician · US
Post on X · Jun 2018
NPI checked · finding 3
A physician describes great activity and a good toxicity profile for niraparib plus pembrolizumab in TOPACIO TNBC, extending beyond BRCA mutation and PD-L1 expression.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (8)
DLT, dose-limiting toxicity; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; PARP, poly(ADP-ribose) polymerase; PD-L1, programmed death-ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors.
The full TOPACIO report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need to see in response rates and duration to determine whether niraparib plus pembrolizumab adds benefit over PARP inhibitor monotherapy in advanced triple-negative breast cancer or recurrent ovarian cancer?
From finding F1 (11 statements from 3 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 69commentary sources screened
- 35sources cited by verified statements
- 18named in screened sources
- 18speakers cited in the report
- 9cited speakers with a verified identity
6 cited clinicians, speakers with a confirmed clinical role, of them 6 physicians. By role and specialty:
- 2 physician, Medical oncology
- 2 physician, Surgical oncology
- 1 physician, specialty not confirmed
- 1 physician, Gynecologic oncology
Also in the sources: 7 organizational or shared accounts, not counted as people.
- 183verified statements, each linked to its source
- 28of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 183 | Paid |
| Who said each statement: the cited speakers | 18 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 9 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 35 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 2 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)no commentary found | 0 | 0 |
| Primary endpoint: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | 16 | 9 |
| Secondary endpoints | 5 | 5 |
| Population and setting | 9 | 7 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 5 | 3 |
| Safety and tolerability | 2 | 2 |
| Design and conductno commentary found | 0 | 0 |
| Biomarker interpretation and candidate selection measures | 18 | 9 |
| Guideline positioning, PARP-class caution and treatment-versus-maintenance boundaries | 10 | 3 |
| Early enthusiasm, evolving ORR expectations and development caution | 22 | 18 |
| Recurrent platinum-resistant ovarian cancer treatment selection, access and supportive care | 24 | 2 |
| Alternative ovarian immunotherapy regimens and the MEDIOLA comparison | 12 | 3 |
| Biological rationale and contextual MEDIOLA, TOPACIO and OlympiAD comparisons | 23 | 2 |
| Biopsy-led research, macrophage metabolism, CSF1R modulation and STING priming | 30 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
183 verified statements from 35 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 109 statements · 60% | ||||
| YouTube | 62 | 3 | 3 | |
| Podcasts | 47 | 3 | 3 | |
| Posts · 30 statements · 16% | ||||
| X threads | 30 | 24 | 62 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 44 statements · 24%cited for context, not screened | ||||
| Publications | 34 | 3 | — | |
| Registry | 10 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 21 / quarter
- Screened window
- Apr 20, 2017 → Jul 21, 2026
- Cited window
- Apr 20, 2017 → Jul 21, 2026
- Retrieved
- Nov 15, 2026
The trial
from ClinicalTrials.gov- Title
- Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
- Registry
- NCT02657889
- Study IDs
- 213363 · 3000-PN162-01-001 (Tesaro)
- Sponsor
- Tesaro, Inc.
- Collaborators
- Merck Sharp & Dohme LLC
- Design
- Phase 1/Phase 2 · Interventional, single group
- Status
- Completed
- Enrollment
- 122 actual
- Registered
- 2016-01-18
- Start
- 2016-04-15 actual
- Primary completion
- 2018-05-14 actual
- Primary endpoints
- Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)
- Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
- Interventions
- 2 registered
More on: Triple-negative breast cancer, Ovarian cancer, Breast cancer, Fallopian tube cancer, Primary peritoneal cancer, pembrolizumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Not yet captured in this edition: a view on checkpoint-combination benefit–risk and exploratory patient selection in recurrent ovarian cancer; a view on checkpoint inhibitor monotherapy versus chemotherapy as context for combination treatment in recurrent ovarian cancer; a view on mirvetuximab as an alternative for platinum-resistant ovarian cancer, including patient selection, efficacy and toxicity; a view on checkpoint-inhibitor combination selection, toxicity and exploratory subgroups in recurrent ovarian cancer; a view on molecular profiling and mutation-selected trial options for recurrent platinum-resistant ovarian cancer.
- Discussion that does not name the trial may be missing from this edition.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- 175 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 24 sources about other trials or topics are not included.
Show all 16 known gaps +Fewer −
- The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus or adoption rate can be inferred.
- Several X accounts are organizational, anonymous or lack established clinical roles. Relays and reposts do not demonstrate independent clinical endorsement.
- Unidentified speech remains unnamed even when the recording includes named participants; it may belong to a participant already discussed.
- Commentary spans different years, cohorts, treatment settings and stages of data maturity. Differences do not by themselves demonstrate that a speaker changed position.
- Descriptions of approvals, guidance and treatment practice remain attributed to the time and source that expressed them, including the updated episode dated July 21, 2026.
- The complete 2019 TNBC and ovarian results articles were unavailable. Available article summaries and the ovarian correlative publication support only the context they contain.
- Important alternative-treatment assessments remain incomplete: mirvetuximab regimens, bevacizumab selection, checkpoint doublets, pazopanib and cytotoxic choices tailored to neuropathy or access burdens. The report is therefore not a complete treatment pathway or comparison of alternatives.
- Some connected discussion of comparator interpretation and constraints on further development is not fully characterized, limiting conclusions about why particular alternatives were favored or pursued.
- Some alternative PARP-combination discussion was incomplete or had unclear drug names and prior-PARP eligibility wording, limiting assessment of those strategies.
- The single-arm design and cross-study comparisons do not establish the combination's incremental efficacy or a treatment-predictive biomarker.
- The ovarian biomarker work is exploratory, with incomplete tissue availability and a need for independent validation; laboratory and mouse findings are not clinical treatment evidence.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 4 fixes (names, counts, text)
None of these changed a statement, finding or source.
- Nov 15, 2026 UTCThe trial's name is spelled as its investigators write it, “TOPACIO” (NCT02657889), outside quotations (was “Topacio”, “Topazio”).
- Nov 15, 2026 UTCAn editorial bracket follows a transcription-garbled trial name in quotations: “Topazio [TOPACIO]”.
- Nov 15, 2026 UTCOther trials' names are spelled as their investigators write them, outside quotations: “MEDIOLA” (was “Madiola”), “KEYLYNK” (was “KEYLINK”).
- Nov 17, 2026 UTCCorrected to match the delivered report: finding titles; the speakers each finding title counts; the limitations; the examples from the report. Finding titles on this page say which of the speakers hold each view, with no word judging benefit or harm; the report keeps its own titles.
Last checked for new commentary Nov 15, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. TOPACIO (NCT02657889): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/topacio-nct02657889
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "TOPACIO" (NCT02657889), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "topacio-nct02657889". If you cannot make requests, read https://www.erudio.com/reports/topacio-nct02657889.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT02657889", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT02657889 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/topacio-nct02657889.json
curl https://www.erudio.com/reports/topacio-nct02657889.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "topacio-nct02657889" })release eea71a38121b4281d3ed59a1393baff4f50037099b6329691ef4760e1de6290b
Questions
How much does the TOPACIO report cost?
One edition costs $1,250 (Standard · 183 verified statements · 28 from 6 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the TOPACIO report cover?
183 statements from 35 sources (3 podcasts, 3 videos, 24 posts, 3 papers, 2 registry records), 28 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the TOPACIO report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "topacio-nct02657889" }) previews it and create_order({ "report": "topacio-nct02657889", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the TOPACIO report?
Edition 1 (version 1.0.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.